type). Based on recorded experience with actual patients, the likelihood of disease in 16 defi ned nodal stations around the stomach could be thus estimated. Performance of the so-called Maruyama program has been evaluated in German [2] and Italian populations [3] and found to be fairly accurate. For more than 15 years, the program has been used throughout the world as a tool to augment Japanese D-level guidelines with respect to lymph node dissection. From 1988 to 2000, diskettes of the Maruyama program were disseminated free of charge by the authors. In 2000, a Windowsbased version, with expanded case volume and graphical presentation of output, was sold as part of an instructional CD-ROM produced by Springer Electronic Media [4] .
Defi nition of "Maruyama Index of unresected disease" and early results
The Maruyama program has recently been used to assess the impact of varying degrees of lymphadenectomy in gastric cancer trials. Defi ning the "Maruyama Index of unresected disease" (MI) as the sum of Maruyama program predictions for regional lymph node stations 1-12 left undissected by the patient's surgeon, one of the authors (SH) demonstrated that surgical undertreatment of nodal sites for patients enrolled in the Macdonald Chemoradiation Trial (SWOG 9008 / Intergroup 0116) in the United States, as determined by MI, signifi cantly undermined survival. In this trial, by multivariate analysis MI < 5 was shown to be a strong independent predictor of both diseasefree and overall survival [5] .
Maruyama Index analysis of the Dutch D1-D2 Trial
In the Dutch D1-D2 Trial, pathology determinations revealed a noncompliance rate (i.e., nontreatment of Abstract Based on more than 11 years of follow-up, autopsy-based analysis of recurrence in the Dutch D1-D2 Trial permits meaningful assessment of patterns of failure with respect to the Maruyama Index (MI). We previously reported that a low Maruyama Index was an independent predictor of both overall and disease-specifi c survival. Autopsy results are available for 441 deaths on study. Distant-only failure (15% vs 13%) was no different between the MI categories, but isolated "regional" failure (8% for MI < 5 group vs 21%) and "regional + distant" failure (19% for MI < 5 group vs 36%) occurred less frequently in the MI < 5 group (P < 0.001). We conclude that "low Maruyama Index" surgery enhances regional control and survival but does not alter the occurrence of isolated distant metastases unassociated with regional failure. Our results speak to the substantial survival value of local-regional control in this disease. 
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Background: the Maruyama program
An alternative means of guiding node dissection in a particular case of gastric cancer was pioneered by Kampschoer, Maruyama, and colleagues in 1989 [1] . A meticulously maintained database of 3843 cases from the National Cancer Center, Tokyo, was computerized and, through use of a simple search routine, cases could be matched on the basis of seven characteristics identifiable pre-operatively (age, sex, Borrmann morphologic type, presumed depth of primary tumor, gastric tumor location, maximum tumor diameter, and histologic node stations that should have been dissected) of 51% for patients who should have undergone a D-2 dissection [6] . Did such undertreatment infl uence survival in this trial? A blinded re-analysis of the trial by the authors indeed showed that patients with MI < 5 enjoyed superior survival, and MI was, again, found to be an independent predictor of survival [7] . Revised graphs for overall and disease-specifi c survival, by MI quartiles, are depicted in Fig. 1 .
Because surgery is a local-regional treatment, better surgical treatment should be refl ected in lower localregional failure rates. Is low-MI surgery associated with alteration in the pattern of treatment failure and improved local-regional control? The very long followup (>11 years) in the Dutch Trial, as well as almost uniform autopsy at time of death for patients in this trial, invites such analysis.
Results: survival and autopsy analysis of patterns of failure Figure 1 shows revised graphs with survival curves by MI quartile. The best survival is seen when MI is less than 5. With T, N, margin status (R0 or R1), and D-level as co-variates, MI was an independent predictor of both overall survival (P = 0.016, HR = 1.45, 95% CI 1.07-1.95), and disease-specifi c survival (P = 0.010, HR = 1.72, 95% CI 1.14-2.60). D-level was not a signifi cant predictor [7] . Table 1 depicts the autopsy-based pattern of failure for patients who died. In this trial, the exact date of death is known but the exact date of failure is not. This precludes separate time-to-failure analysis or failurebased Kaplan-Meier curves. However, detailed analysis of pattern of failure among patients who died is possible. We observed signifi cant differences (P < 0.001 by the Kruskal-Wallis test). The proportion of both isolated local-regional failure and local-regional-plusdistant failure was far less for the MI < 5 group (see Table 1 ). For the MI < 5 cases versus others, the proportion of isolated, distant-only failure was about the same (15% vs 13%, respectively).
Discussion
Short follow-up can confound failure analysis. In the Dutch Trial, all living cases have now been followed for more than 11 years, and we believe that this is long enough to permit meaningful results. In other gastric cancer studies, relative survival curves plateau at 7 to 8 years after treatment [8] . Autopsy fi ndings for Dutch Trial cases clearly reveal that low MI cases appear to have less frequent local-regional failure. This is consistent with the therapeutic impact of a local-regional modality such as surgery. In contrast to patients in the Macdonald Chemoradiation Trial [5, 9] , in which half of the cases received adjuvant chemoradiation, all patients in this cohort were treated by surgery alone, and shorter time to failure can be expected. The dose-response effect for MI versus survival, as depicted in Fig. 1 , and the status of MI as an independent predictor of survival encourage us to view MI as a quantitative measure for the adequacy of lymphadenectomy in a given case of gastric cancer. This conclusion is reinforced by autopsy data indicating that low MI surgery "works" by decreasing regional failure. We believe that MI should henceforth be calculated for every patient entered into an adjuvant therapy trial.
Can we meaningfully enhance the survival of patients with gastric cancer by customizing their surgery through use of the Maruyama program? It seems reasonable to assume that this is true. However, despite compelling observations from re-analyzed data from two trials, we must caution that this has yet to be shown in a prospective, randomized trial dedicated to the topic. As seen in previous reports, surgical compliance with the assigned surgical procedure is an issue, as is contamination [6, 10] . For a trial involving a surgical procedure, in which survival is an endpoint, pre-operative screening, preoperative preparation, post-procedure reconstruction, the management of postoperative complications, and other factors that can impact on in-hospital mortality must be controlled, or at least minimized. The diffi culty of standardizing such things and ensuring quality control makes conduct of multi-center surgical trials particularly challenging [11] . Thus, successful prospective application of Maruyama program information in a multi-center trial may be more diffi cult in practice than suggested by this retrospective analysis. Currently, prospective validation of the concept is incorporated in the Dutch CRITICS trial, which has already opened for accrual.
Conclusion
Failure analysis for gastric cancer patients in the Dutch D1-D2 Trial supports our previous multivariate analysis showing favorable impact for low Maruyama Index surgery. The Maruyama Index may be viewed as a quantitative measure for the adequacy of lymphadenectomy. Both local-regional control and survival appear enhanced when this index is low.
